10-K: Maravai LifeSciences Holdings Reports Fiscal Year 2024 Results; Announces Strategic Acquisitions

Maravai LifeSciences Holdings details its financial performance for 2024, highlighting challenges and strategic moves including acquisitions to bolster its nucleic acid production capabilities.

Summary

• Maravai LifeSciences Holdings reported its financial results for the fiscal year ended December 31, 2024.
• The company experienced a revenue decrease of 10.3%, with total revenue at $259.2 million compared to $288.9 million in 2023.
• Revenue from Nucleic Acid Production decreased by 12.6% to $196.3 million, while Biologics Safety Testing revenue decreased by 2.1% to $62.8 million.
• The company recorded a goodwill impairment charge of $166.2 million, impacting the TriLink and Alphazyme reporting units.
• Maravai completed the acquisition of Molecular Assemblies' assets and intellectual property in January 2025 for $11.5 million.
• In February 2025, Maravai acquired Officinae Bio for an initial $10.0 million plus potential contingent consideration up to $35.0 million.
• The company voluntarily prepaid $228.0 million on its term loan in December 2024.
• Maravai's workforce includes over 570 full-time employees globally, with 27.7% holding advanced degrees.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While the company is making strategic acquisitions, it is also facing financial challenges and has identified material weaknesses in its internal control over financial reporting.

Positives

• Maravai completed strategic acquisitions of Molecular Assemblies and Officinae Bio to enhance its nucleic acid production business.
• The company voluntarily prepaid $228.0 million on its term loan, reducing its debt burden.
• The company continues to invest in research and development to support customer needs.
• The company has a diverse global customer base, including top biopharmaceutical companies and academic institutions.

Negatives

• Maravai experienced a 10.3% decrease in revenue for fiscal year 2024.
• The company recorded a $166.2 million goodwill impairment charge, indicating a decline in the value of certain assets.
• The company identified material weaknesses in its internal control over financial reporting.
• The company is subject to a putative securities class action lawsuit.

Risks

• The company is dependent on customer spending and demand for outsourced nucleic acid production and biologics safety testing products and services.
• The company's operating results are prone to significant fluctuations, making future results difficult to predict.
• The company faces competition from larger life science, pharmaceutical, and biotechnology companies.
• The company's products could become subject to more onerous regulation by the FDA or other regulatory agencies.
• The company's ability to use net operating loss and tax credit carryforwards is limited by provisions of the Internal Revenue Code.

Future Outlook

The company expects to experience further declines in high-volume sales of CleanCap and is unable to fully estimate the impact of unused inventory on future revenues. The company plans to continue a strategy of growth and development for its business.

Management Comments

• Management uses Adjusted EBITDA to evaluate the financial performance of our business and the effectiveness of our business strategies.
• Management is responsible for establishing and maintaining adequate internal control over financial reporting.

Industry Context

The announcement reflects the broader trend of biopharmaceutical companies relying on outside parties for critical inputs and services, while also navigating challenges such as market fluctuations and competition.

Comparison to Industry Standards

• The document does not provide specific comparisons to industry standards.
• The document does not provide specific comparisons to comparable companies.
• The document does not provide specific comparisons to global benchmarks.

Legal Proceedings

• The company is currently subject to a putative securities class action lawsuit.

Related Party Transactions

• The company made cash distributions of $0.5 million for tax liabilities to MLSH 1 under the Topco LLC Operating Agreement.
• The company made payments of $7.3 million to MLSH 1 and MLSH 2 pursuant to the Tax Receivable Agreement.

Stakeholder Impact

• Shareholders may be concerned about the decrease in revenue and the goodwill impairment charge.
• Employees may be affected by the cost realignment plan and the termination of approximately 15% of the workforce.
• Customers may be impacted by the company's ability to provide reliable, high-quality life science reagents.

Next Steps

• The company plans to continue a strategy of growth and development for its business.
• The company is in the process of designing appropriate controls as well as implementing measures to ensure appropriate operation of existing controls to address the identified material weaknesses.

Key Dates